Most clinical trials of antipsychotics have focused on short-term efficacy and were conducted under conditions close to ideal with regard to patient selection, monitoring, and adherence to treatment. As a result, the amount of available data relevant to the real-world effectiveness that emerge from these trials has been subject of debate. The NIMH sponsored Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) was developed to address these limitations. The CATIE study includes elderly patients who have dementia with psychosis and/or agitation, and studies sequential treatment representative of the population actually seen in the clinics, and outcome measures selected to reflect real-world effectiveness as closely as possible. The rationale and the implications of this innovative approach will be critically discussed.
Back to S108 Atypical Antipsychotic Drugs for the Treatment of Psychiatric Symptoms of Dementia: A New Look at Meaningful Outcomes
Back to Satellite Symposia
Back to The Eleventh International Congress